Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The
official language of this press release is Japanese, and the Japanese version takes
precedence over the English version in terms of content and interpretation.

<Press Release>
August 29, 2022
Chordia's licensee Ono Pharmaceutical Co., Ltd. initiated Phase 1 Study of ONO7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory NonHodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
Kanagawa, Japan, August 29, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech
company engaged in the research and development of novel therapies for cancers,
today announced that ONO PHARMA USA, Inc., the U.S. subsidiary of Ono
Pharmaceutical Co., Ltd. (ONO) initiated a Phase 1 study of ONO-7018 (CTX-177),a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1)
inhibitor, licensed from Chordia in 2020, in patients with relapsed or refractory nonHodgkin lymphoma (“NHL”) or chronic lymphocytic leukemia (“CLL”) in the U.S.
This study is a multicenter, open label, dose escalation Phase 1 study (ONO-7018-01)
to evaluate ONO-7018 in patients with relapsed or refractory NHL or CLL. For more
information, please visit the following website at clinicaltrials.gov/ (NCT05515406).
As for CTX-177 (ONO-7018), Chordia licensed the MALT1 inhibitor to ONO inDecember 2020. ONO has exclusive global rights to develop, manufacture, andcommercialize CTX-177 (ONO-7018).
For more information, please visit https://www.chordiatherapeutics.com/wp/wpcontent/uploads/2021/05/20201215_Notice-of-license-agreement_EN.pdf
About Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia(CLL)
NHL and CLL arise from the accumulation of monoclonal B or T lymphocytes in thebody. Once NHL and CLL become refractory to standard chemotherapy and antibodybased therapies, the overall prognosis is poor, with limited long-term survival. Thus,
novel and effective therapies are needed to address this high unmet medical need. NHLis the most common of lymphoid malignancies in the U.S. and Europe with more than70,000 new cases diagnosed every year. CLL is the most common of leukemia in
adults with an estimated 20,160 new cases in the U.S. in 2022.
About CTX-177 (ONO-7018)
CTX-177 (ONO- 7018) is a selective inhibitor against a mucosa-associated lymphoidtissue lymphoma translocation protein 1 (MALT1), which is known to be involved in
an intracellular signaling pathway in lymphocytic blood cells. Activation of MALT1
is reported to play an important role in malignancies of lymphocytes. CTX-177 (ONO7018) is expected to exert anti-tumor effect against these malignancies by inhibitingof MALT1 activity. CTX-177 (ONO-7018) is an investigational agent that has notChordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
info@chordiatherapeutics.com

been approved for any indication in any country. Safety and efficacy have not been
established.
About ONO PHARMA USA, INC.
ONO PHARMA USA, INC. (“OPUS”), established in 1998 as the U.S. subsidiary of
Ono Pharmaceutical Co., Ltd. ("ONO”), is pursuing the clinical development of new
drug candidates and aiming to establish its operation from the clinical development
until the regulatory approval of products for commercialization in the U.S. In addition,
OPUS has been engaged in promotion of the discovery alliances and licensing
activities to expand ONO’s development pipeline and to pursue the commercialization
opportunities in the U.S. For more information, please visit the company’s website athttps://www.ono-usa.com/.
About Chordia Therapeutics
Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture,
Japan, engaged in the research and development of novel therapies for cancers.
Chordia’s lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan.
CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver
benefit to patients of various types of cancer. In addition to CTX-712, Chordia isengaged in the research of several preclinical assets, including CTX-439, a CDK12inhibitor, which is expected to be effective in cancers with specific abnormalities, aswell as GCN2 inhibitors.
Established:
Address:
Representative:
Website:November 2017
26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Hiroshi Miyake, Representative Director
https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com